Of course I will be - I continue to watch this even though I'm no longer invested (I initially bought in September 2015 at 1.8c). Bought and sold and finally sold out around 10c (and won't go back in).
I think it is way overvalued at its current market cap, and at this price there are considerably more downside risks than upside potential.
I don't begrudge anyone a profit, and I hope it does payoff for all of you. But IMO with a high market cap already, even with FDA approval the potential upside isn't worth the downside risk (which is basically 100%). Ask yourself what happens to RAP if the FDA don't approve it? The company is gone overnight if that happens. I've seen it happen to more than one ASX company - everyone riding high on the 'sure thing', just need to tick a few boxes with the FDA, and then bam, no FDA approval. Directors don't know what happened, everyone crying for their blood. Company is gone. All IMO of course.
- Forums
- ASX - By Stock
- RAP
- Ann: ResAppDx to be Formally Evaluated by Doctors Without Borders
Ann: ResAppDx to be Formally Evaluated by Doctors Without Borders, page-111
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review